Research Interests: Immune response, Flow Cytometry, Biology, Inflammation, Immunohistochemistry, and 15 moreCell separation, Biopsy, Humans, Blood, Drug Resistance, Immunotherapy, Glycoproteins, Interferon, CD, Clinical Sciences, Enzyme Linked Immunosorbent Assay, Immunoglobulins, Interferon Alpha, Interferon gamma, and Cardiovascular medicine and haematology
Research Interests:
Research Interests: Neuroscience, Fluorescence Microscopy, Biology, Neurodegeneration, Medicine, and 15 morePrion Diseases, Brain, Humans, Mice, Animals, Peripheral Nervous System, Phosphorylation, Neurons, Peripheral nerves, Peripheral Nerve, Disease Progression, Brain Chemistry, Prion Protein, Axonal transport, and Medical and Health Sciences
A post-marketing study was conducted in 26 paediatric practices in Germany to collect safety information on the virosomal adjuvanted influenza vaccine Inflexal V (in Germany marketed as Infectovac Flu). Children aged 6 months to 6 years... more
A post-marketing study was conducted in 26 paediatric practices in Germany to collect safety information on the virosomal adjuvanted influenza vaccine Inflexal V (in Germany marketed as Infectovac Flu). Children aged 6 months to 6 years received one or two doses. Adverse events were documented by parents/legal guardians in a questionnaire for four days after vaccination. The rates of adverse events were low: 14% of vaccine exposures were associated with systemic and 25% with local adverse events. Most symptoms were mild to moderate and resolved within a few days. Nearly 100% of parents/legal guardians would agree to have their child vaccinated again with Inflexal V. Vaccination with Inflexal V was safe, well tolerated and highly accepted by parents/legal guardians.
Research Interests:
Research Interests:
Research Interests:
Research Interests: Flow Cytometry, Inflammation, Immunohistochemistry, Cell separation, Biopsy, and 15 moreMeasles Virus, Humans, Blood, Drug Resistance, Oncolytic Viruses, Immunotherapy, Glycoproteins, Clinical Sciences, Lymphocytes, Enzyme Linked Immunosorbent Assay, Immunoglobulins, Interferon Alpha, Interferon gamma, Cardiovascular medicine and haematology, and Paediatrics and reproductive medicine
Measles virus (MV) has shown promise as an oncolytic virus in the treatment of different tumor models for human B-cell lymphoma, multiple myeloma, ovarian cancer, and glioma. We have shown that, in a phase I clinical trial, MV vaccine... more
Measles virus (MV) has shown promise as an oncolytic virus in the treatment of different tumor models for human B-cell lymphoma, multiple myeloma, ovarian cancer, and glioma. We have shown that, in a phase I clinical trial, MV vaccine induces tumor regression in cutaneous T-cell lymphoma (CTCL) patients. Here, we investigated in detail, the effect of recombinant MV (rMV) vaccine